Los puntos clave no están disponibles para este artículo en este momento.
TcRζ/CD3 and TcRζ/CD3-CD28 signaling requires the guanine nucleotide exchange factor (GEF) Vav-1 as well as the activation of phosphatidylinositol 3-kinase, protein kinase B (PKB/AKT), and its inactivation of glycogen synthase kinase-3 (GSK-3). Whether these two pathways are connected or operate independently of each other in T-cells has been unclear. Here, we report that anti-CD3 and anti-CD3/CD28 can induce PKB and GSK-3α phosphorylation in the Vav-1–/– Jurkat cell line J. Vav.1 and in primary CD4-positive Vav-1–/– T-cells. Reduced GSK-3α phosphorylation was observed in Vav-1,2,3–/– T-cells together with a complete loss of FOXO1 phosphorylation. Furthermore, PKB and GSK-3 phosphorylation was unperturbed in the presence of GEF-inactive Vav-1 that inhibited interleukin-2 gene activation and a form of Src homology 2 domain-containing lymphocytic protein of 76-kDa (SLP-76) that is defective in binding to Vav-1. The pathway also was intact under conditions of c-Jun N-terminal kinase (JNK) inhibition and disruption of the actin cytoskeleton by cytochalasin D. Both events are down-stream targets of Vav-1. Overall, our findings indicate that the TcR and TcR-CD28 driven PKB-GSK-3 pathway can operate independently of Vav-1 in T-cells. TcRζ/CD3 and TcRζ/CD3-CD28 signaling requires the guanine nucleotide exchange factor (GEF) Vav-1 as well as the activation of phosphatidylinositol 3-kinase, protein kinase B (PKB/AKT), and its inactivation of glycogen synthase kinase-3 (GSK-3). Whether these two pathways are connected or operate independently of each other in T-cells has been unclear. Here, we report that anti-CD3 and anti-CD3/CD28 can induce PKB and GSK-3α phosphorylation in the Vav-1–/– Jurkat cell line J. Vav.1 and in primary CD4-positive Vav-1–/– T-cells. Reduced GSK-3α phosphorylation was observed in Vav-1,2,3–/– T-cells together with a complete loss of FOXO1 phosphorylation. Furthermore, PKB and GSK-3 phosphorylation was unperturbed in the presence of GEF-inactive Vav-1 that inhibited interleukin-2 gene activation and a form of Src homology 2 domain-containing lymphocytic protein of 76-kDa (SLP-76) that is defective in binding to Vav-1. The pathway also was intact under conditions of c-Jun N-terminal kinase (JNK) inhibition and disruption of the actin cytoskeleton by cytochalasin D. Both events are down-stream targets of Vav-1. Overall, our findings indicate that the TcR and TcR-CD28 driven PKB-GSK-3 pathway can operate independently of Vav-1 in T-cells. T-cell activation is induced by ligation of the antigen-receptor (TcRζ/CD3) as well as co-receptors such as CD28. TcRζ/CD3 and CD4/CD8-lck initiate tyrosine phosphorylation, while TcRζ/CD3 and CD28 induce the production of D-3 lipids (1Rudd C.E. Schneider H. Nat. Rev. Immunol. 2003; 3: 544-556Crossref PubMed Scopus (307) Google Scholar, 2Abraham R.T. Weiss A. Nat. Rev. Immunol. 2004; 4: 301-308Crossref PubMed Scopus (396) Google Scholar). CD28 co-signals are needed for optimal cytokine production, proliferation, and effector function (3Bluestone J.A. Immunity. 1995; 2: 555-559Abstract Full Text PDF PubMed Scopus (520) Google Scholar, 4June C.H. Bluestone J.A. Nadler L.M. Thompson C.B. Immunol. Today. 1994; 15: 321-331Abstract Full Text PDF PubMed Scopus (198) Google Scholar). CD28-deficient mice have reduced responses to antigen, highlighting the capacity of CD28 to lower the threshold of signaling (5Shahinian A. Pfeffer K. Lee K.P. Kundig T.M. Kishihara K. Wakeham A. Kawai K. Ohashi P.S. Thompson C.B. Mak T.W. Science. 1993; 261: 609-612Crossref PubMed Scopus (1171) Google Scholar). Primary responses exhibit more of a dependence on CD28 than do secondary responses, and the co-receptor can influence the differentiation of T helper 2 (Th2) versus T helper 1 (Th1) cell, increase cell survival, and prevent the induction of T-cell anergy (3Bluestone J.A. Immunity. 1995; 2: 555-559Abstract Full Text PDF PubMed Scopus (520) Google Scholar, 6Dahl A.M. Klein C. Andres P.G. London C.A. Lodge M.P. Mulligan R.C. Abbas A.K. J. Exp. Med. 2000; 191: 2031-2038Crossref PubMed Scopus (52) Google Scholar, 7Schwartz R.H. Curr. Opin. Immunol. 1997; 9: 351-357Crossref PubMed Scopus (229) Google Scholar). The molecular basis of TcRζ/CD3 and CD28 signaling in T-cells has been the subject of much investigation. TcRζ/CD3 engagement with CD4/CD8-p56lck leads to the recruitment of ZAP-70 and the phosphorylation of multiple adaptors (8Rudd C.E. Cell. 1999; 96: 5-8Abstract Full Text Full Text PDF PubMed Scopus (189) Google Scholar, 9Weiss A. Littman D.R. Cell. 1994; 76: 263-274Abstract Full Text PDF PubMed Scopus (1957) Google Scholar). TcR and CD28 ligation can increase the expression of lipid rafts or microdomains (10Viola A. Schroeder S. Sakakibara Y. Lanzavecchia A. Science. 1999; 283: 680-682Crossref PubMed Scopus (842) Google Scholar, 11Martin M. Schneider H. Azouz A. Rudd C.E. J. Exp. Med. 2001; 194: 1675-1681Crossref PubMed Scopus (118) Google Scholar). Furthermore, CD28 can be distinguished from the TcR by virtue of the fact that it directly interacts with phosphatidylinositol 3-kinase (PI3K) 2The abbreviations used are: PI3K, phosphatidylinositol 3-kinase; SH, Src homology; IL, interleukin; PKB, protein kinase B; GSK, glycogen synthase kinase-3; NFAT, nuclear factor of activated T-cell; DH, Dbl homology; JNK, c-Jun N-terminal kinase; WT, wild-type; FACS, fluorescence-activated cell sorter; RαM, rabbit anti-mouse; RαH, rabbit anti-hamster; GEF, guanine nucleotide exchange factor; FITC, fluorescein isothiocyanate. by means of classic p85 Src homology 2 (SH2) domain binding to a cytoplasmic YMNM motif (12Prasad K.V. Cai Y.C. Raab M. Duckworth B. Cantley L. Shoelson S.E. Rudd C.E. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 2834-2838Crossref PubMed Scopus (269) Google Scholar, 13Pages F. Ragueneau M. Rottapel R. Truneh A. Nunes J. Imbert J. Olive D. Nature. 1994; 369: 327-329Crossref PubMed Scopus (347) Google Scholar, 14Hehner S.P. Hofmann T.G. Dienz O. Droge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar). Additional proline residues of CD28 mediate supplemental binding to the Src homology 3 (SH3) domains of Grb-2 and p56lck (15Kim H.H. Tharayil M. Rudd C.E. J. Biol. Chem. 1998; 273: 296-301Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar, 16Holdorf A.D. Green J.M. Levin S.D. Denny M.F. Straus D.B. Link V. Changelian P.S. Allen P.M. Shaw A.S. J. Exp. Med. 1999; 190: 375-384Crossref PubMed Scopus (147) Google Scholar). Mutations in both sets of residues attenuate CD28-mediated signaling (16Holdorf A.D. Green J.M. Levin S.D. Denny M.F. Straus D.B. Link V. Changelian P.S. Allen P.M. Shaw A.S. J. Exp. Med. 1999; 190: 375-384Crossref PubMed Scopus (147) Google Scholar, 17Burr J.S. Savage N.D. Messah G.E. Kimzey S.L. Shaw A.S. Arch R.H. Green J.M. J. Immunol. 2001; 166: 5331-5335Crossref PubMed Scopus (130) Google Scholar, 18Okkenhaug K. Wu L. Garza K.M. La Rose J. Khoo W. Odermatt B. Mak T.W. Ohashi P.S. Rottapel R. Nat. Immunol. 2001; 2: 325-332Crossref PubMed Scopus (172) Google Scholar, 19Cai Y.C. Cefai D. Schneider H. Raab M. Nabavi N. Rudd C.E. Immunity. 1995; 3: 417-426Abstract Full Text PDF PubMed Scopus (123) Google Scholar, 20Cefai D. Cai Y.C. Hu H. Rudd C. Int. Immunol. 1996; 8: 1609-1616Crossref PubMed Scopus (26) Google Scholar). In vivo re-constitution studies have provided mixed results in the role of the YMNM motif in interleukin-2 (IL-2) production and graft versus host responses (17Burr J.S. Savage N.D. Messah G.E. Kimzey S.L. Shaw A.S. Arch R.H. Green J.M. J. Immunol. 2001; 166: 5331-5335Crossref PubMed Scopus (130) Google Scholar, 18Okkenhaug K. Wu L. Garza K.M. La Rose J. Khoo W. Odermatt B. Mak T.W. Ohashi P.S. Rottapel R. Nat. Immunol. 2001; 2: 325-332Crossref PubMed Scopus (172) Google Scholar, 21Harada Y. Tokushima M. Matsumoto Y. Ogawa S. Otsuka M. Hayashi K. Weiss B.D. June C.H. Abe R. J. Immunol. 2001; 166: 3797-3803Crossref PubMed Scopus (78) Google Scholar). The production of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate lipids by PI3K leads to the membrane recruitment and activation of protein kinase B (PKB/AKT) that in turn can phosphorylate and inactivate glycogen synthase kinase-3 (GSK-3) (22Cantley L.C. Science. 2002; 296: 1655-1657Crossref PubMed Scopus (4681) Google Scholar, 23Lawlor M.A. Alessi D.R. J. Cell Sci. 2001; 114: 2903-2910Crossref PubMed Google Scholar). In resting T-cells, GSK-3 negatively regulates IL-2 transcription by phosphorylating nuclear factor of activated T-cells (NFATs), leading to its translocation from the nucleus (24Woodgett J.R. Curr. Opin Cell Biol. 2005; 17: 150-157Crossref PubMed Scopus (311) Google Scholar, 25Liang J. Slingerland J.M. Cell Cycle. 2003; 2: 339-345Crossref PubMed Scopus (698) Google Scholar). CD28 ligation can potentiate PKB and/or GSK-3 phosphorylation (26Appleman L.J. van Puijenbroek A.A. Shu K.M. Nadler L.M. Boussiotis V.A. J. Immunol. 2002; 168: 2729-2736Crossref PubMed Scopus (168) Google Scholar, 27Frauwirth K.A. Riley J.L. Harris M.H. Parry R.V. Rathwell J.C. Plas D.R. Elstrom R.L. June C.H. Thompson C.B. Immunity. 2002; 16: 679-777Abstract Full Text Full Text PDF Scopus (762) Google Scholar). In this context, PKB has been implicated in the regulation of IL-2 production but not Th2 cytokines (28Kane L.P. Andres P.G. Howland K.C. Abbas A.K. Weiss A. Nat. Immunol. 2001; 2: 37-44Crossref PubMed Scopus (270) Google Scholar). PI3K-PKB also regulate Fas-mediated apoptosis (29Ohteki T. Parsons M. Zakarian A. Jones R.G. Nguyen L.T. Woodgett J.R. Ohashi P.S. J. Exp. Med. 2000; 192: 99-104Crossref PubMed Scopus (127) Google and in T-cells K.A. Riley J.L. Harris M.H. Parry R.V. J.C. Plas D.R. Elstrom R.L. June C.H. Thompson C.B. Immunity. 2002; 16: Full Text Full Text PDF PubMed Scopus Google Scholar). In to the PI3K TcRζ/CD3 and CD28 signaling is on the guanine nucleotide exchange Vav-1. has a homology a two and a domain Cell. Biol. 2000; PubMed Scopus Google Scholar, M. Nat. Rev. Immunol. 2002; 2: PubMed Scopus Google Scholar, Curr. Opin. Immunol. 2005; 17: PubMed Scopus Google Scholar, M. A. Immunol. Today. 1997; Full Text PDF PubMed Scopus Google Scholar). The domain of Vav-1 tyrosine residues the domain-containing lymphocytic protein of (SLP-76) M.A. S.E. N. J. Immunol. 1997; Google Scholar, M. S. Rudd C.E. Immunity. 2001; 15: Full Text Full Text PDF PubMed Scopus Google Scholar). residues each a both of are The Dbl homology domain has for the activation of the and M. M. J.S. 1996; Google Scholar). T-cells in TcR and the induction of cytokine production A. M. S. L.P. K. Nature. 1995; PubMed Scopus Google Scholar, H. K. T. M. S. M.P. D. M. A. J.M. Curr. Biol. 1998; 8: Full Text Full Text PDF PubMed Google Scholar). of Vav-1 by CD28 on residues of the (15Kim H.H. Tharayil M. Rudd C.E. J. Biol. Chem. 1998; 273: 296-301Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar, S. F. Olive D. Immunol. 1998; PubMed Scopus Google Scholar). CD28 has been to TcR signaling F. L. A. A. Olive D. O. J. Immunol. 2000; PubMed Scopus Google Scholar). Furthermore, can translocation the nucleus of in to CD28 ligation M. S. Rudd C.E. Immunity. 2001; 15: Full Text Full Text PDF PubMed Scopus Google Scholar). In CD28 engagement can kinase and activation in a Vav-1 F. C. B. A. M. L. R.T. L. J. Immunol. 2003; PubMed Scopus Google Scholar). In has that and in to CD28 F. C. B. A. M. L. R.T. L. J. Immunol. 2003; PubMed Scopus Google Scholar). Vav-1 has been to with protein kinase to c-Jun kinase (JNK) A. Dienz O. S.P. W. Schmitz M.L. J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google while Jurkat in as well as in the activation of and transcription needed for interleukin-2 transcription Y. A. D. R.T. J. 2002; PubMed Scopus Google Scholar). that TcR and TcR-CD28 that on Vav-1 and PI3K, is these pathways are or operate independently of each have been mixed in other Vav-1 has been to be on lipids to homology domain binding and J. K. B. Shu Y. U. J.R. M.A. D. Science. 1998; PubMed Scopus Google Scholar). inhibition of PI3K not phosphorylation in K. M. A.M. N. J. T. J. Exp. Med. 2002; PubMed Scopus (123) Google Scholar). studies have a or role for Vav-1 in PI3K C. R. S. J. Cell. Biol. 2002; Scopus Google Scholar, T. N. J. D. J. Exp. Med. 2002; PubMed Scopus Google Scholar, M. 2004; PubMed Scopus Google Scholar). activation of protein kinase B phosphorylation in M. 2004; PubMed Scopus Google Scholar). In this we report that anti-CD3 and anti-CD3/CD28 can induce PKB and GSK-3 phosphorylation in the Vav-1–/– Jurkat cell line and in primary CD4-positive Vav-1–/– T-cells. Reduced but GSK-3 phosphorylation was also observed in Vav-1,2,3–/– T-cells, a complete loss of FOXO1 phosphorylation. Furthermore, PKB and GSK-3 phosphorylation was unperturbed in the presence of a GEF-inactive form of a that IL-2 gene of phosphorylation also observed in the presence of a form of that is defective in Vav-1 binding and in with cytochalasin to the findings indicate that TcR and TcR-CD28 can induce signaling independently of Vav-1 in T-cells. and Jurkat T-cell line was cell The Jurkat cell line and a from La and Vav-1–/– mice a from for Vav-1,2,3–/– mice provided by T-cells from from and Vav-1–/– mice in the of a of T-cells that than for as by used for the of the Vav-1,2,3–/– was from was from and CD28 with rabbit that the of primary was and CD28 from with rabbit that the of primary or for the and of and Jurkat with of the and of a and for in to the Jurkat in of the for in a and was a and the from of GSK-3 and PKB Jurkat or the Jurkat cell or 3 T-cells from of or Vav-1–/– mice in on a with the primary for and with for the by of in and by The used in from and secondary the of and PKB phosphorylation was as a of the of to protein expression by the or with the of cytochalasin for 1 in 1 and in and with 2 anti-CD3 for with or and was by on or for 1 was to the and with and on TcR was by T-cells for TcR in each as was used to anti-CD3 for 1 was to the and with by was by with and a the the PI3K and Vav-1 pathways in to TcR and TcR-CD28 we to that anti-CD3 and anti-CD3/CD28 induced PKB and GSK-3 phosphorylation and anti-CD3/CD28 used for of on Jurkat for was by of cell with a to of PKB or to and on GSK-3α and PKB phosphorylation by to the 2 versus was with versus also induced PKB phosphorylation to as or than observed with anti-CD3 3 versus with to PKB of protein expression In of the phosphorylation was with the of phosphorylation by versus The and was of phosphorylation results with the two GSK-3 GSK-3α was to the in T-cells. with PKB phosphorylation, anti-CD3 GSK-3α phosphorylation to the 2 versus phosphorylation was with versus also induced GSK-3α phosphorylation the of protein expression The that and anti-CD3/CD28 induce phosphorylation of PKB and GSK-3α in T-cells. Vav-1 expression was for PKB and GSK-3α phosphorylation, was in the Jurkat cell line Y. A. D. R.T. J. 2002; PubMed Scopus Google Scholar). and induced of PKB or GSK-3α phosphorylation in Vav-1–/– that with that observed in and versus of the of phosphorylation in the lower The of Vav-1 was by versus that anti-CD3 and anti-CD3/CD28 induction of PKB and GSK-3α phosphorylation in T-cells can independently of Vav-1 The of phosphorylation on Vav-1 expression with the in and signaling in the Y. A. D. R.T. J. 2002; PubMed Scopus Google Scholar). this pathway was intact in primary Vav-1–/– T-cells, we also PKB and GSK-3 phosphorylation in T-cells from of or Vav-1–/– for with or by of PKB versus and GSK-3α phosphorylation versus The of Vav-1 was by versus The in the of phosphorylation. a in PKB and GSK-3 phosphorylation in Vav-1–/– the was more than with T-cells a loss of GSK-3 phosphorylation in phosphorylation was that GSK-3 phosphorylation is on and that is a pathway that is this with the transcription factor FOXO1 phosphorylation was indicate that anti-CD3 and induction of PKB-GSK-3 phosphorylation can in the of Vav-1 expression and is reduced with the loss of the Vav-1 and the phosphorylation, we Vav-1 a domain with PKB and GSK-3α phosphorylation of the of the Jurkat with Vav-1 or the induced phosphorylation of PKB and GSK-3α in with or and and versus and also induced of phosphorylation in WT, and and and Vav-1 expression was with versus The expression of PKB and was by with the lower and lower GSK-3α and PKB phosphorylation by lower the of on the PKB-GSK-3 as by Cell. Biol. 2000; PubMed Scopus Google Scholar, A. M. S. L.P. K. Nature. 1995; PubMed Scopus Google expression of inhibited and IL-2 transcription the of the on T-cell indicate that the TcR and pathway is intact in the presence of a Vav-1 domain that can IL-2 transcription in T-cells. that the of the domain on IL-2 transcription independently of the PKB-GSK-3 Vav-1 has also been to with the protein J. Weiss A. Immunity. 1996; 4: Full Text Full Text PDF PubMed Scopus Google Scholar, H. J. Biol. Chem. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar, M. Rudd C.E. Immunity. 1997; Full Text Full Text PDF PubMed Scopus (189) Google by the Vav-1 domain binding to two on M. Rudd C.E. Immunity. 1997; Full Text Full Text PDF PubMed Scopus (189) Google Scholar). studies have that Vav-1 and can in the induction of IL-2 that is with of the J. Weiss A. Immunity. 1996; 4: Full Text Full Text PDF PubMed Scopus Google Scholar, H. J. Biol. Chem. 1996; Full Text Full Text PDF PubMed Scopus Google Scholar, M. Rudd C.E. Immunity. 1997; Full Text Full Text PDF PubMed Scopus (189) Google Scholar). PKB and GSK-3 phosphorylation operate independently of the Vav-1 binding to on or induced phosphorylation of PKB and and versus versus was by and versus as M.A. S.E. N. J. Immunol. 1997; Google while expression IL-2 as by the loss of the Vav-1 binding to this increase findings that PKB and GSK-3α phosphorylation can Vav-1 and the of anti-CD3 and anti-CD3/CD28 of from we also the pathway operate the activation of targets of Vav-1. Vav-1 can regulate activation and actin cytoskeleton Cell. Biol. 2000; PubMed Scopus Google Scholar, M. Nat. Rev. Immunol. 2002; 2: PubMed Scopus Google Scholar). the regulation of these events have to the regulation of PKB-GSK-3 on it was of to the pathway in the of these the role of JNK, with the that have been to W. J.C. A. S. Y. A.M. Proc. Natl. Acad. Sci. U. S. A. 2001; PubMed Scopus Google Scholar). In this we to of GSK-3 phosphorylation induced of GSK-3α phosphorylation in 2 versus and lower of GSK-3 protein of GSK-3α phosphorylation was observed in that been with cytochalasin in a of reduced of its on the cytoskeleton M. Rudd C.E. Immunity. 1997; Full Text Full Text PDF PubMed Scopus (189) Google In on the cell was by cytochalasin and lower and anti-CD3/CD28 to induce of GSK-3α phosphorylation a of cytochalasin In in a increase in phosphorylation was observed the of the the that the inhibition of the disruption of the cytoskeleton with cytochalasin with the induction of GSK-3α phosphorylation. The of the the and pathways has been the of mixed Vav-1 has been to on lipids J. K. B. Shu Y. U. J.R. M.A. D. Science. 1998; PubMed Scopus Google while have a role for Vav-1 in PI3K K. M. A.M. N. J. T. J. Exp. Med. 2002; PubMed Scopus (123) Google Scholar, C. R. S. J. Cell. Biol. 2002; Scopus Google Scholar, T. N. J. D. J. Exp. Med. 2002; PubMed Scopus Google Scholar, M. 2004; PubMed Scopus Google Scholar). it has been that the inhibition of PI3K not phosphorylation in C. R. S. J. Cell. Biol. 2002; Scopus Google while activation of PKB in J. Weiss A. Immunity. 1996; 4: Full Text Full Text PDF PubMed Scopus Google Scholar). this it was to these pathways in T-cells. is in the of CD28 the and PI3K and is also by Vav-1 (12Prasad K.V. Cai Y.C. Raab M. Duckworth B. Cantley L. Shoelson S.E. Rudd C.E. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 2834-2838Crossref PubMed Scopus (269) Google Scholar, 13Pages F. Ragueneau M. Rottapel R. Truneh A. Nunes J. Imbert J. Olive D. Nature. 1994; 369: 327-329Crossref PubMed Scopus (347) Google Scholar, 14Hehner S.P. Hofmann T.G. Dienz O. Droge W. Schmitz M.L. J. Biol. Chem. 2000; 275: 18160-18171Abstract Full Text Full Text PDF PubMed Scopus (81) Google Scholar, H.H. Tharayil M. Rudd C.E. J. Biol. Chem. 1998; 273: 296-301Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar, 16Holdorf A.D. Green J.M. Levin S.D. Denny M.F. Straus D.B. Link V. Changelian P.S. Allen P.M. Shaw A.S. J. Exp. Med. 1999; 190: 375-384Crossref PubMed Scopus (147) Google Scholar, 17Burr J.S. Savage N.D. Messah G.E. Kimzey S.L. Shaw A.S. Arch R.H. Green J.M. J. Immunol. 2001; 166: 5331-5335Crossref PubMed Scopus (130) Google Scholar, 18Okkenhaug K. Wu L. Garza K.M. La Rose J. Khoo W. Odermatt B. Mak T.W. Ohashi P.S. Rottapel R. Nat. Immunol. 2001; 2: 325-332Crossref PubMed Scopus (172) Google Scholar, 19Cai Y.C. Cefai D. Schneider H. Raab M. Nabavi N. Rudd C.E. Immunity. 1995; 3: 417-426Abstract Full Text PDF PubMed Scopus (123) Google Scholar, 20Cefai D. Cai Y.C. Hu H. Rudd C. Int. Immunol. 1996; 8: 1609-1616Crossref PubMed Scopus (26) Google Scholar, 21Harada Y. Tokushima M. Matsumoto Y. Ogawa S. Otsuka M. Hayashi K. Weiss B.D. June C.H. Abe R. J. Immunol. 2001; 166: 3797-3803Crossref PubMed Scopus (78) Google Scholar, K.A. Riley J.L. Harris M.H. Parry R.V. J.C. Plas D.R. Elstrom R.L. June C.H. Thompson C.B. Immunity. 2002; 16: Full Text Full Text PDF PubMed Scopus Google Scholar, M. S. Rudd C.E. Immunity. 2001; 15: Full Text Full Text PDF PubMed Scopus Google Scholar, F. L. A. A. Olive D. O. J. Immunol. 2000; PubMed Scopus Google Scholar). findings that anti-CD3 and induced of PKB and GSK-3α phosphorylation in Vav-1–/– Jurkat and primary CD4-positive T-cells 1 and that Vav-1 is not for the activation of the PKB-GSK-3 pathway in T-cells. of phosphorylation observed in the presence of a Vav-1 domain that is well in its to IL-2 transcription that the domain has in TcR driven IL-2 transcription that is of the PKB-GSK-3 the of of the Vav-1 binding of a of and the PKB-GSK-3 in T-cells are to observed in activation of PKB in the of Vav-1 M. 2004; PubMed Scopus Google Scholar). Vav-1 is the of the in T-cells. studies have that Vav-1–/– in TcR and IL-2 production A. M. S. L.P. K. Nature. 1995; PubMed Scopus Google Scholar, H. K. T. M. S. M.P. D. M. A. J.M. Curr. Biol. 1998; 8: Full Text Full Text PDF PubMed Google Scholar, M. A. Immunol. Today. 1997; Full Text PDF PubMed Scopus Google Scholar, Y. A. D. R.T. J. 2002; PubMed Scopus Google Scholar). the expression of other that Vav-1 can a or role in these from our findings with the PKB-GSK-3 in the of Vav-1–/– T-cells, Vav-1,2,3–/– a loss of GSK-3 phosphorylation. that the of the in a of In this other for Vav-1 in the T-cells to for PKB and GSK-3 phosphorylation. the GSK-3 phosphorylation was observed in the of with the complete loss of phosphorylation in these The of the pathway to this activation to be other a pathway loss the threshold of or a pathway from that the activation of GSK-3 The of activation from Vav-1 was observed with both anti-CD3 and anti-CD3/CD28 to a dependence on Vav-1 with CD28 this was not the was by the of to potentiate PKB and GSK-3 phosphorylation as well as IL-2 a increase in and PKB and GSK-3 phosphorylation was observed in and Vav-1–/– 1 and The increase in The in the of phosphorylation with activation was the of other pathways that regulate PKB and PKB A. J. Biol. Chem. 2000; 275: Full Text Full Text PDF PubMed Scopus Google phosphorylation by kinase M. C. V. L. Woodgett J. S. Proc. Natl. Acad. Sci. U. S. A. 1998; PubMed Scopus Google Scholar, S. S. V. N. D. L. J. M.P. S. J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google and in lipid rafts J. Curr. Biol. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar). was that GSK-3α was to be the of phosphorylation in T-cells of GSK-3α and expression in Jurkat and primary T-cells. was observed with both anti-CD3 and The GSK-3α to be or to its phosphorylation in T-cells. with other the of GSK-3 is the primary of phosphorylation (24Woodgett J.R. Curr. Opin Cell Biol. 2005; 17: 150-157Crossref PubMed Scopus (311) Google Scholar, 25Liang J. Slingerland J.M. Cell Cycle. 2003; 2: 339-345Crossref PubMed Scopus (698) Google Scholar). also that GSK-3α is the effector in the regulation of events such as in the nucleus of T-cells. is the our results and in a on T. N. J. D. J. Exp. Med. 2002; PubMed Scopus Google Scholar). to in PKB activation T. N. J. D. J. Exp. Med. 2002; PubMed Scopus Google Scholar). the basis of this is it be to a in the of or a T-cells and it is that lower of ligation are more on Vav-1 expression than of also conditions that or of in turn increase the dependence on Vav-1. in to these we the of or the cytoskeleton on PKB and GSK-3 phosphorylation. it be that Vav-1 signaling to the engagement of it also have been in its to the studies that is or defective in T-cells, while expression of PI3K not c-Jun binding by Y. A. D. R.T. J. 2002; PubMed Scopus Google Scholar, J. S. L. S. A. M.P. M. Biol. Cell. 1998; 9: PubMed Scopus Google Scholar). of on anti-CD3 or anti-CD3/CD28 phosphorylation of GSK-3 disruption of the actin cytoskeleton with cytochalasin on GSK-3 activation is the of signaling events that are to on intact In this the cytoskeleton is to as a that signaling for PKB and GSK-3 phosphorylation was in with of cytochalasin that the that intact cytoskeleton is not needed for the of TcRζ/CD3 CD28 to induce GSK-3α phosphorylation and with a that intact GSK-3 phosphorylation in to in cytochalasin M.L. Cell. Biol. 2004; PubMed Scopus Google Scholar). studies be needed to the of pathways by PI3K that operate independently of Vav-1. for and for mice in Vav-1 and
Wood et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: